Cara TherapeuticsCARA
CARA
About: Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Employees: 55
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
7.95% less ownership
Funds ownership: 32.62% [Q2] → 24.67% (-7.95%) [Q3]
10% less capital invested
Capital invested by funds: $4.6M [Q2] → $4.15M (-$447K) [Q3]
14% less funds holding
Funds holding: 81 [Q2] → 70 (-11) [Q3]
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
85% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 33
Research analyst outlook
We haven’t received any recent analyst ratings for CARA.
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cara Therapeutics, Inc. (NasdaqCM: CARA) and Tvardi Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Cara shareholders are expected to own approximately 17.0% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are ad.
Neutral
GlobeNewsWire
3 weeks ago
Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “ Company ”), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 will be effective as of 5:00 p.m. Eastern Time on Monday, December 30, 2024.
Neutral
PRNewsWire
1 month ago
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cara Therapeutics, Inc. - CARA
NEW YORK , Dec. 18, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Cara Therapeutics, Inc. (NASDAQ: CARA ), relating to the proposed merger with Tvardi Therapeutics, Inc. Under the terms of the agreement, Cara Therapeutics stockholders are expected to own approximately 17.0% of the combined company.
Neutral
Business Wire
1 month ago
CARA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cara Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Cara Therapeutics, Inc. (NASDAQ: CARA) and Tvardi Therapeutics, Inc. is fair to Cara shareholders. Upon completion of the proposed transaction, Cara shareholders are expected to own approximately 17.0% of the combined company. Halper Sadeh encourages Cara shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 7.
Neutral
Business Wire
1 month ago
Shareholder Alert: Ademi LLP Investigates Whether Cara Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Cara (NASDAQ: CARA) for possible breaches of fiduciary duty and other violations of law in its transaction with Tvardi. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, pre-Merger Cara stockholders are expected to own approximately 17.0% of the combined company and pre-Merger Tvardi i.
Neutral
GlobeNewsWire
1 month ago
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases
Negative
Benzinga
7 months ago
These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'
Shares of Cara Therapeutics Inc CARA tanked in early trading on Thursday, with the Dow shedding more than 100 points.
Negative
InvestorPlace
7 months ago
Why Is Cara Therapeutics (CARA) Stock Down 27% Today?
Cara Therapeutics (NASDAQ: CARA ) stock is falling hard on Thursday after the development-stage biopharmaceutical company announced new data from a clinical trial. This data comes from the company's Part A KOURAGE-1 study.
Negative
Reuters
7 months ago
Cara Therapeutics discontinues study on a neurological condition as drug fails
Cara Therapeutics said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its experimental drug did not demonstrate a meaningful clinical benefit compared to placebo.
Neutral
GlobeNewsWire
7 months ago
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica (NP).
Charts implemented using Lightweight Charts™